NCT01309438 - A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions

HealthyRenal Insufficiency

Interventions

DRUG

Rivaroxaban (normal renal function)

One 10 mg tablet of rivaroxaban taken orally (by mouth) on Day 1 of Treatment Period 1; One 10 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 2

DRUG

Rivaroxaban (mild and moderate renal impairment)

One 10 mg tablet of rivaroxaban taken orally (by mouth) on Day 1 of Treatment Period 1; One 5 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 2; One 10 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 3

DRUG

Erythromycin (normal renal function)

One 500 mg tablet taken orally (by mouth) three times daily on Days 1 to 6 of Treatment Period 2

DRUG

Erythromycin (mild and moderate renal function)

One 500 mg tablet taken orally (by mouth) three times daily on Days 1 to 6 of Treatment Periods 2 and 3

Trial Locations (4)

Unknown

Orlando

Minneapolis

Saint Paul

Knoxville